Case Report

Signet Ring Cell Carcinoma of the Colon in Young Adults: A Case Report and Literature Review

Farida Abi Farraj,1 Hadi Sabbagh,1 Tarek Aridi,1 Najla Fakhruddin,2,3 and Fadi Farhat4

1Faculty of Medicine, American University of Beirut, Beirut, Lebanon
2Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon
3Department of Pathology, Hammoud Hospital University Medical Center, Saida, Lebanon
4Department of Oncology, Hammoud Hospital University Medical Center, Saida, Lebanon

Correspondence should be addressed to Fadi Farhat; drfadi.clinic@gmail.com

Farida Abi Farraj and Hadi Sabbagh contributed equally to this work.

Received 3 June 2019; Accepted 24 August 2019; Published 11 September 2019

Academic Editor: Yu-Fei Jiao

Copyright © 2019 Farida Abi Farraj et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Colorectal cancer (CRC), one of the leading causes of cancer-related deaths, presents with challenging features related to its diagnosis and management. The incidence of CRC in the adolescent and young adult (AYA) population has increased over the past couple of decades despite the decline in the overall occurrence of CRC in the general population. Signet ring cell carcinoma is one of the rare histopathologic subtypes of CRC; however, it is more prevalent in AYA patients than in older adults and presents with unconventional histologic characteristics, a distinct clinical behavior, and a poor prognosis. We report a case of a primary signet ring cell adenocarcinoma of the ascending colon in a 19-year-old male who presented with unusual signs and symptoms and was diagnosed with stage IVA (T4a N0 M1, with peritoneal seeding). The unusual presentation and location of the tumor in this case warrant further investigation.

1. Introduction

Colorectal cancer (CRC) is ranked second among women and third among men [1]. CRC overall incidence has declined over the past few years possibly due to screening by colonoscopy in patients above the age of 50 [2]. Contrarily, the incidence of CRC among patients younger than 50 years has increased at a rate of 1.5% and 1.6% in males and females, respectively. Nevertheless, CRC prevalence remains lower among young adults (20-40 years) compared to older adults (>40 years) with an incidence of 2.4% and 97.6%, respectively [3, 4].

CRC in young adults (20-40 years) has been shown to be more commonly located on the left side [4]. A recent analysis showed that younger CRC patients are more likely to present with adverse histological features, specifically vascular and perineural invasion, with positive circumferential margins after resection [5]. Also, CRC in younger patients is likely to be associated with inflammatory bowel disease, other CRC-related syndromes, and a positive family history [6]. Prognostically, current evidence is still conflicting. One population-based analysis with SEER data reported that younger patients tend to present with advanced stages but have similar outcomes as older patients [7] while others reported that younger patients tend to have poorer prognoses [8].

Signet ring cell carcinoma (SRCC) variant of CRC is an aggressive and rare entity that accounts for about less than 1% of the cases of CRC [9]. However, SRCC is more common as a CRC variant among young adults than older adults and leads to more aggressive outcomes primarily because of its late detection [9].

This paper reports a rare case of a 19-year-old male diagnosed with stage IVA signet ring cell adenocarcinoma (T4a N0 M1, with peritoneal seeding) of the ascending colon, a location that is rather uncommon in this age group. A
A previously healthy 19-year-old nonsmoker Caucasian male presented with acute epigastric pain, of 2-day duration, radiating to the right upper quadrant. Also, recurrent episodes of projectile and nonbloody vomiting as well as watery and nonbloody diarrhea occurred over a period of 2 months. He has no significant family history of gastrointestinal disease or cancer. On physical examination, the abdomen was soft with tenderness around the right lower quadrant. An abdominal CT scan revealed significant and irregular circumferential thickening of the ascending colon wall that suggests intussusception (Figure 2(a)). Subsequently, the patient underwent an exploratory laparoscopy.

**Hx:** Severe abdominal pain, of 2 days duration, localized in the epigastrium and right upper quadrant, with several episodes of non-bloody vomiting and watery diarrhea. The same episode of symptoms had occurred once 2 months prior to admission.

**Physical examination:**
(i) No fever and no chills
(ii) Normal chest and cardiac findings
(iii) Soft abdomen, with positive bowel sounds and tenderness around the right lower quadrant
(iv) No peripheral edema

**Investigations:**
(i) **CT of the abdomen with IV contrast:** Extensive fecal loading of the ascending colon and extensive circumferential wall thickening of the ascending colon, suggestive of intussusception involving the ascending colon.
(ii) **Diagnostic laparoscopy:** Identification of a tumor in the right ascending colon with peritoneal seedings
(iii) **Open right hemicolecotomy:**
   (i) Removal of the suspicious specimen
   (ii) Wedge resection of the duodenum invaded by the tumor
   (iii) Ileo-transverse anastomosis
(iv) **Liver biopsy from a suspicious liver lesion**

**Diagnosis Confirmed by Pathology:**
Colorectal Adenocarcinoma, Signet-ring cell type

**Management:**
Patient underwent 11 cycles of chemotherapy composed of Bevacizumab (IV) and Oxaliplatin (IV) and Capecitabine (PO).

**Follow up abdominal CT post right hemicolecotomy procedure:** Minimal omental thickening and stranding with minimal residual nodularities that might represent peritoneal deposits.

**Follow up abdominal CT post chemotherapy completion:** Resolution of the peritoneal nodularities.

**Follow up PET scan after one year:** complete remission of tumor.

**PET scan on March 18, 2018 revealed complete remission**

2. Case Presentation

A previously healthy 19-year-old nonsmoker Caucasian male presented with acute epigastric pain, of 2-day duration, radiating to the right upper quadrant. Also, recurrent episodes of projectile and nonbloody vomiting as well as watery and nonbloody diarrhea occurred over a period of 2 months. He has no significant family history of gastrointestinal disease or cancer. On physical examination, the abdomen was soft with tenderness around the right lower quadrant. An abdominal CT scan revealed significant and irregular circumferential thickening of the ascending colon wall that suggests intussusception (Figure 2(a)). Subsequently, the patient underwent an exploratory laparoscopy.

**Hx:** Severe abdominal pain, of 2 days duration, localized in the epigastrium and right upper quadrant, with several episodes of non-bloody vomiting and watery diarrhea. The same episode of symptoms had occurred once 2 months prior to admission.

**Physical examination:**
(i) No fever and no chills
(ii) Normal chest and cardiac findings
(iii) Soft abdomen, with positive bowel sounds and tenderness around the right lower quadrant
(iv) No peripheral edema

**Investigations:**
(i) **CT of the abdomen with IV contrast:** Extensive fecal loading of the ascending colon and extensive circumferential wall thickening of the ascending colon, suggestive of intussusception involving the ascending colon.
(ii) **Diagnostic laparoscopy:** Identification of a tumor in the right ascending colon with peritoneal seedings
(iii) **Open right hemicolecotomy:**
   (i) Removal of the suspicious specimen
   (ii) Wedge resection of the duodenum invaded by the tumor
   (iii) Ileo-transverse anastomosis
(iv) **Liver biopsy from a suspicious liver lesion**

**Diagnosis Confirmed by Pathology:**
Colorectal Adenocarcinoma, Signet-ring cell type

**Management:**
Patient underwent 11 cycles of chemotherapy composed of Bevacizumab (IV) and Oxaliplatin (IV) and Capecitabine (PO).

**Follow up abdominal CT post right hemicolecotomy procedure:** Minimal omental thickening and stranding with minimal residual nodularities that might represent peritoneal deposits.

**Follow up abdominal CT post chemotherapy completion:** Resolution of the peritoneal nodularities.

**Follow up PET scan after one year:** complete remission of tumor.

**PET scan on March 18, 2018 revealed complete remission**

Figure 1: Timeline organizing the main events of the case.
that revealed a tumor in the ascending colon with peritoneal seeding. Right hemicolectomy followed by an ileo-transverse anastomosis was performed, and a suspicious liver lesion was identified intraoperatively and resected for investigation. The pathology reported a poorly differentiated signet ring cell adenocarcinoma of the ascending colon with metastasis to the omentum and involvement of the pericolonic fat. The surgical margins were negative, with the absence of lymphovascular invasion and 24 dissected lymph nodes free of tumor. The liver biopsy was negative for metastasis. According to the TNM/AJCC staging system, the tumor is stage IV (T4a N0 M1, with peritoneal seeding) (Figure 3). Immunohistochemistry for MLH1, MSH2, MSH6, and PMS2 showed the absence of mutations for microsatellite instability (Figure 4). Gene mutation analysis by PCR sequence specific oligonucleotide probes (SSOP) for KRAS, NRAS, and BRAF genes detected no mutations (Table 1).

The patient was started on 11 cycles (each cycle spanned 2 weeks) of bevacizumab (400 mg) and oxaliplatin (160 mg) with 3 tablets of capecitabine (500 mg) twice daily over 10 days. The patient complied to and completed the protocol. Follow-up by MRI one month after the hemicolectomy showed an ill-defined and diffuse omental enhancement. Three months later, a CT scan of the abdomen demonstrated minimal omental thickening and stranding with minimal residual nodularities (Figure 2(b)). After completing the 11 cycles of chemotherapy, a CT scan showed resolution of the peritoneal nodularities (Figure 2(c)). Chemotherapy treatment was arrested after considering the patient’s status, prognosis, and risk of recurrence. On one-year follow-up, a PET scan revealed complete remission of the tumor.

3. Discussion

The vast majority of signet ring cell carcinoma (SRCC) arise in the stomach. Other less common locations of this tumor include the gallbladder, pancreas, colon, rectum, bladder, and breast [10, 11]. Hence, it is important to rule out a stomach origin of tumor via imaging and biopsies. As in our case, the absence of lesions in the stomach and the presence of a colonic mass confirm the diagnosis of a primary SRCC of the colon.

SRCC is an uncommon histologic variant of CRC accounting for less than 1% of all histological subtypes. Unlike other subtypes of CRCs, SRCC among the young (ages 20-40 years) is four times more prevalent than among older adults (>40 years) [4]. SRCC is defined as a rare and aggressive malignancy of the glandular lining of the digestive tract with cells that appear as signet rings under microscopy [12]. The signet ring-like appearance of these cells results from the excess mucin accumulating within them pushing the nuclei to the peripheries. These cells are often associated with pools of extracellular mucin [13].

In this paper, we report a case of SRCC in a 19-year-old male with an uncommon presentation of intussusception.
by radiology and right-sided tumor location with complete remission post chemotherapy after one-year follow-up.

Classically, colorectal cancer patients present with symptoms of abdominal pain, blood in stools, unintentional weight loss, and changes in bowel habits [14]. The symptoms of colorectal SRCC are typically similar to those of colorectal cancers (Table 2). However, our case and few other cases of right-sided SRCC in young adults did not adopt the conventional presentation of CRC and rather mainly involved episodes of vomiting [15–17]. It is important to note that the latter presentation of right-sided SRCC is unique to young adults as older patients with right-sided SRCC present with classical symptoms of colorectal cancer such as abdominal pain and rectal bleed [18]. The primary workup depends on the status of the patient. A CT scan or an ultrasound imaging of the abdomen is usually part of the initial workup on a patient presenting with abdominal pain to specifically exclude an acute abdomen [19]. In our case, the patient underwent a CT scan that revealed a configuration of the colon highly suggestive of intussusception, which is a common finding in cases of colorectal cancer in young patients that might blur the diagnosis [20]. A colonoscopy and biopsy of the mucosa are also part of the workup usually following the initial imaging tests. However, because of the suggestion of intussusception, our patient was subjected to an exploratory laparoscopy that revealed a mass in the right colon and necessitated the conversion to an open laparotomy.

SRCC in younger adults is more commonly located in the left colon. Only 3 out of the 29 cases, including our case, presented with right colon involvement (Table 2). In contrast to young adults, in a retrospective review of patients with SRCC, with most cases being above 40 years of age, SRCC in older adults was shown to be more prevalent in the right colon [18]. Right colon tumors are known to have a worse prognosis with lower 5-year specific survival rate and 5-year disease-free survival rate [20]. The worse prognosis could be attributed to the different genetic and epigenetic alterations between right and left colorectal cancer, as well as the different molecular pathways that affect the course of the disease and impact its management [21]. Patients with signet ring cell carcinoma of the colon tend to have an overall poor survival rate compared to patients with other histologic subtypes, mainly due to the vague and late presentation of the symptoms [21]. A recent multivariate adjusted survival analysis on the National Cancer Data Base (NCDB) showed that signet ring cell histology is associated with 57% higher risk of death relative to nonmucinous and nonsignet ring adenocarcinoma for both colon and rectal cancers [9]. Another surveillance study compared the

Table 1: The mutations tested and their corresponding genes for our patient.

| Gene | Mutations |
|------|-----------|
| KRAS | Codons: 12-13-59-60-61-117-146 |
| NRAS | Codons:12-13-59-60-61-146 |
| BRAF | V600A-V600D-V600E-V600G-V600K-V600M-V600R-K601E |

Figure 4: Immunohistochemistry testing for mismatch repair proteins. All proteins show intact nuclear expression: (a) MLH1, (b) MSH2, (c) MSH6, and (d) PMS2.
Table 2: Main clinicopathological parameters of SRCC of the colon cases reported in the literature.

| No. | Citations                  | Age (years) | Gender | History of IBD | Family history | Polyps | Location | Tumor size (cm) | Lymph nodes | Distant metastasis | Chemotherapy | Survival |
|-----|----------------------------|-------------|--------|----------------|----------------|--------|----------|-----------------|-------------|-------------------|--------------|----------|
| 1   | Seo et al. [27]            | 39          | M      | UC            | N/A            | −      | R        | 0.8             | +           | −                 | N/A          | Alive    |
| 2   | Tamai et al. [28]          | 37          | F      | N/A           | N/A            | −      | TC       | 7.0             | N/A         | +                 | −            | Deceased |
| 3   | Shimizu et al. [29]        | 38          | M      | UC            | N/A            | +      | R        | 1.5             | −           | −                 | N/A          | N/A      |
| 4   | Posey et al. [30]          | 25          | M      | N/A           | N/A            | −      | R        | N/A             | +           | +                 | +            | Deceased |
| 5   | Nakata et al. [31]         | 22          | F      | N/A           | N/A            | −      | DC       | 1.5             | −           | −                 | N/A          | Alive    |
| 6   | Adnane et al. [32]         | 30          | F      | N/A           | N/A            | −      | R        | 10.6            | +           | −                 | N/A          | Alive    |
| 7   | Kilickap et al. [33]       | 29          | M      | N/A           | N/A            | −      | R        | N/A             | +           | +                 | +            | N/A      |
| 8   | Maltz and Schwartz [34]    | 35          | M      | CD            | N/A            | −      | SC       | N/A             | +           | +                 | N/A          | Deceased |
| 9   | Derici et al. [35]         | 23          | M      | −             | +              | −      | R        | N/A             | +           | −                 | −            | −        |
| 10  | Selcukbircik et al. [36]   | 37          | F      | N/A           | N/A            | −      | SC       | N/A             | +           | +                 | +            | N/A      |
| 11  | Canepa et al. [37]         | 40          | M      | −             | N/A            | −      | R        | 7.0             | +           | −                 | +            | N/A      |
| 12  | Charles et al. [38]        | 24          | M      | N/A           | N/A            | +      | R        | N/A             | +           | +                 | +            | N/A      |
| 13  | Kang et al. [10]           | 21          | M      | −             | N/A            | +      | R        | 0.5             | −           | −                 | N/A          | N/A      |
| 14  | Mehta et al. [39]          | 37          | M      | N/A           | N/A            | +      | SC       | N/A             | +           | +                 | +            | N/A      |
| 15  | Pamukçu et al. [19]        | 19          | M      | N/A           | N/A            | −      | SC       | N/A             | N/A         | N/A               | +            | N/A      |
| 16  | Richer et al. [15]         | 19          | F      | N/A           | N/A            | +      | AC       | 6.0             | +           | N/A               | N/A          | N/A      |
| 17  | Shaaban et al. [40]        | 30          | F      | N/A           | N/A            | −      | R        | 6.0             | +           | +                 | +            | Deceased |
| 18  | Kendre et al. [41]         | 34          | M      | N/A           | N/A            | −      | R        | N/A             | +           | +                 | +            | Alive    |
| 19  | Prabhu et al. [16]         | 28          | F      | −             | N/A            | −      | TC       | N/A             | −           | −                 | +            | Alive    |
| 20  | Dhull et al. [42]          | 26          | F      | N/A           | N/A            | −      | R        | 10.0            | −           | −                 | +            | N/A      |
| 21  | Santos-Antunes et al. [43] | 32          | M      | N/A           | N/A            | −      | AC       | N/A             | N/A         | N/A               | −            | Deceased |
| 22  | Yadav et al. [44]          | 19          | M      | N/A           | N/A            | −      | RC       | N/A             | +           | −                 | +            | Alive    |
| 23  | Park et al. [45]           | 36          | F      | N/A           | N/A            | −      | C        | 4.9             | −           | −                 | +            | N/A      |
| 24  | Turati et al. [46]         | 29          | M      | N/A           | N/A            | −      | R        | 8.3             | +           | +                 | +            | Alive    |
| 25  | Zhou et al. [47]           | 27          | M      | N/A           | N/A            | −      | TC       | N/A             | N/A         | +                 | N/A          | Alive    |
| 26  | Khan et al. [17]           | 20          | M      | N/A           | N/A            | +      | TC       | N/A             | +           | +                 | +            | N/A      |
| 27  | Lusila et al. [48]         | 25          | M      | N/A           | N/A            | −      | R        | N/A             | −           | +                 | +            | Deceased |
| 28  | Ren et al. [49]            | 31          | F      | −             | N/A            | −      | R        | N/A             | +           | −                 | +            | N/A      |
| 29  | Our case                   | 19          | M      | −             | −              | −      | AC       | N/A             | +           | +                 | +            | Alive    |

M: male; F: female; IBD: inflammatory bowel disease; CD: Crohn’s disease; UC: ulcerative colitis; R: rectum; TC: transverse colon; DC: descending colon; SC: sigmoid colon; AC: ascending colon; C: cecum; N/A: not available.
survival of patients with right-sided SRCC to patients with left-sided SRCC and revealed that patients with right-sided SRCC had lower mortality rates in stage II disease [22]. Such an association in younger adults with SRCC is to be established yet.

Recent studies proved the effective role of adjunct chemotherapy, in accord with surgical resection of the tumor, in late stages of SRCC and prolonging the overall survival [23]. In our case, the therapeutic protocol consisted of 3 chemotherapeutic regimens following the surgical resection of the tumor and proved to be successful in treating the patient.

The molecular profile of SRCC is associated with lower prevalence of KRAS and NRAS mutations, higher prevalence of BRAF and CIMP (CpG island methylator phenotype) mutations, and a lower expression of p16 and p53 [24]. However, SRCC has been associated with a significantly reduced expression of E-cadherin adhesion protein that complexes with catenin proteins to maintain the polarity of epithelial cells. The invasive phenotype of SRCC is enhanced by the acquired motility of cells owing to the reduced expression of E-cadherin molecules [25]. KRAS, NRAS, and BRAF gene mutations were not detected in this case (Table 1). A recent whole-exome and RNA sequencing study demonstrated that the difference concerning the molecular basis of colorectal SRCC and nonsignet conventional colorectal adenocarcinoma is that the former is usually richer in SRCC-specific genes that result in epithelial-mesenchymal transition (EMT) and stem cell upregulation which contribute to the invasiveness of such tumors [26].

SRCC is associated with distant lymph node metastasis, in addition to more advanced stages at presentation, which significantly worsens its prognosis relative to other colorectal cancers [9, 24]. The literature on young SRCC patients revealed 17 out of 29 cases with lymph node involvement and 14 out of 29 cases with distant metastasis (Table 2). Our case presented with metastasis to the omentum and involvement of the pericolonic fat, with the absence of metastasis to the lymph nodes and liver.

Studies on young patients (<40 years) that have SRCC of colorectal origin are scarce; about 29 cases have only been reported in the literature (Table 2). A history of inflammatory bowel disease like ulcerative colitis (2/29) and Crohn’s disease (1/29) is not common in young SRCC patients. This finding was similar in older adult SRCC patients [18]. A positive family history was reported in 4 out of 29 cases only; and 3 out of 29 cases had polyps. Metastasis was reported in around half of the cases (14/29). Additionally, 18 out of the 29 patients received chemotherapy with only 5 long-term survivors. The rest of the patients with distant metastasis had either died (5/14) or were lost to follow-up (5/14). Among the 12 patients with localized disease, only one of them died. These findings stress the importance of early diagnosis and treatment.

4. Conclusion

We conclude that SRCC, a rare histopathologic subtype of CRC that is more prevalent in young adults than in older adults, has a distinct clinical presentation and an unconventional localization in the colon that warrant a conclusive workup. It is important to consider SRCC in our differential of an AYA patient presenting with prolonged and vague gastrointestinal symptoms, as SRCC is an aggressive subtype of CRC with poorer prognosis if detected in an advanced state. Moreover, it is important to rule out a primary GI malignancy that has metastasized to an atypical location in the colon. Additional assessment of the molecular characteristics of this aggressive subtype of CRC further improves the therapeutic modalities of this disease that can result in a good prognosis.

Abbreviations

CD: Crohn’s disease
CRC: Colorectal cancer
CT: Computed tomography
IBD: Inflammatory bowel disease
MRI: Magnetic resonance imaging
NCDB: National Cancer Data Base
PCR: Polymerase chain reaction
PET: Positron emission tomography
SRCC: Signet ring cell carcinoma
SCARE: Surgical CAse REports
UC: Ulcerative colitis

Ethical Approval

This report was carried out in accordance with the recommendations of the Institutional Review Boards (IRB) of the Hammoud Hospital University Medical Center (HHUMC) with written informed consent from the included subject.

Consent

The patient gave written informed consent in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patient for participation in this case report and its publication with the accompanying images. A copy of the written consent is available upon request for review by the editor-in-chief of this journal.

Conflicts of Interest

The authors declare that this research was conducted in the absence of financial or commercial affiliations that could be understood as a potential conflict of interest.

Authors’ Contributions

FAF and NF worked on the study design and conception. HS, FAF, and TA contributed to the data collection, screening titles for relevance, and abstracting the relevant data from full-text articles. NF worked on the pathology figures and performed the necessary experiments and molecular analysis. TA and HS worked on the illustration of figures and drafting of the timeline. FAF, HS, and NF analyzed the data and drafted the manuscript. FAF and HS provided other authors with explanations about the case reported. TA and NF revised critically and edited the manuscript.
NF was responsible for the study supervision and conduction of the project as a whole. All authors read and approved the final draft. Farida Abi Farraj and Hadi Sabbagh equally contributed to this work.

Acknowledgments

The authors would like to thank the patient whose case is presented here and his family for giving us their permission to publish this case report and Hamhoud Hospital University Medical Center for the permission to disclose the information needed.

References

[1] K.-M. She, H.-M. Wang, J.-B. Chen et al., “Colorectal cancer in younger than 30 years old group is not associated with poor prognosis,” Journal of Society of Colon and Rectal Surgeons (Taiwan), vol. 22, pp. 93–98, 2011.

[2] S. H. Kang, W. S. Chung, C. L. Hyun et al., “Preoperative diagnosis of colorectal signet ring cell carcinoma using whole-exome and RNA sequencing,” Translational Oncology, vol. 11, no. 4, pp. 800–805, 2018.

[3] M. Z. Qiu, W. T. Pan, J. Z. Lin et al., “Comparison of survival between right-sided and left-sided colon cancer in different situations,” Cancer Medicine, vol. 7, no. 4, pp. 1141–1150, 2018.

[4] J. Sun, X. Wang, P. Gao et al., “Prognosis and efficiency of adjuvant therapy in resected colon signet-ring cell carcinoma,” Translational Cancer Research, vol. 7, no. 4, pp. 1006–1025, 2018.

[5] J. B. P. Harrington, G. S. Smith, G. R. Lam et al., “Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinomas: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features,” Modern Pathology, vol. 25, no. 8, pp. 1128–1139, 2012.

[6] H. Goldvasser, O. Purim, Y. Kundel et al., “Colorectal cancer in young patients: is it a distinct clinical entity?,” International Journal of Clinical Oncology, vol. 21, no. 4, pp. 684–695, 2016.

[7] J. B. Parramore, J. P. Wei, and K. A. Yeh, “Colorectal cancer in patients under forty: presentation and outcome,” The American Surgeon, vol. 64, no. 6, pp. 563–567, 1998.

[8] G. M. D’Onofrio and E. G. C. Tan, “Is colorectal carcinoma in the young a more deadly disease?,” ANZ Journal of Surgery, vol. 38, no. 5, pp. 337–340, 1985.

[9] J. R. Hylgstrom, C. Y. Hyun, Y. Xing et al., “Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base,” Annals of Surgical Oncology, vol. 19, no. 9, pp. 2814–2821, 2012.

[10] S. H. Kang, W. S. Chung, C. L. Hyun et al., “A rare case of a signet ring cell carcinoma of the colon mimicking a juvenile polyp,” Gut and Liver, vol. 6, no. 1, pp. 129–131, 2012.

[11] S. Y. Tung, C. S. Wu, and P. C. Chen, “Primary signet ring cell carcinoma of colorectum: an age- and sex-matched controlled study,” American Journal of Gastroenterology, vol. 91, no. 10, pp. 2195–2199, 1996.

[12] National Cancer Institute, “Nci dictionary of cancer terms,” 2018, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/signet-ring-cell-carcinoma.

[13] U. Nitsche, A. Zimmermann, C. Späth et al., “Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis,” Annals of Surgery, vol. 258, no. 5, pp. 775–783, 2013.

[14] S. Simon, “Signs and symptoms of colorectal cancer,” 2018, https://www.cancer.org/latest-news/signs-and-symptoms-of-colon-cancer.html.

[15] V. Richer, D. Bonnaud, and N. Provost, “Signet-ring cell colon cancer in a 19-year-old patient with giant congenital cellular blue nevus of the scalp,” International Journal of Dermatology, vol. 52, no. 8, pp. 1021–1023, 2013.

[16] R. Prabhu, N. Kumar, S. Krishna, and R. Shenoy, “Primary colonic signet ring cell carcinoma in a young patient,” Case Reports, vol. 2014, 2014.

[17] M. Khan, K. Korphaissarn, A. Saif, W. C. Foo, and S. Kopetz, “Early-onset signet-ring cell adenocarcinoma of the colon: a case report and review of the literature,” Case Reports in Oncological Medicine, vol. 2017, Article ID 2832180, 7 pages, 2017.

[18] L. Messerini, A. Palomba, and G. Zampi, “Primary signet-ring cell carcinoma of the colon and rectum,” Diseases of the Colon & Rectum, vol. 38, no. 11, pp. 1189–1192, 1995.

[19] O. Pamukçu, F. Selukbircik, A. Bilici, D. Sakiz, O. Ozdoğan, and F. Borlu, “Signet cell carcinoma of colon in a nineteen-year-old patient: a case report,” Case Reports in Oncological Medicine, vol. 2013, Article ID 695450, 4 pages, 2013.

[20] J. Marone, S. Patel, M. Page, and P. Cheriyath, “Signet cell carcinoma of the colon in a 17 year old child,” Journal of Surgical Case Reports, vol. 2012, no. 9, p. 3, 2012.

[21] I. Sultan, C. Rodriguez-Galindo, H. el-Taami et al., “Distinct features of colorectal cancer in children and adolescents: a population-based study of 159 cases,” Cancer, vol. 116, no. 3, pp. 758–765, 2010.

[22] M. Z. Qiu, W. T. Pan, J. Z. Lin et al., “Comparison of survival between right-sided and left-sided colon cancer in different situations,” Cancer Medicine, vol. 7, no. 4, pp. 1141–1150, 2018.

[23] J. Sun, X. Wang, P. Gao et al., “Prognosis and efficiency of adjuvant therapy in resected colon signet-ring cell carcinoma,” Translational Cancer Research, vol. 7, no. 4, pp. 1006–1025, 2018.

[24] V. Gopalan, R. A. Smith, Y. H. Ho, and A. K. Y. Lam, “Signet-ring cell carcinoma of colorectum — current perspectives and molecular biology,” International Journal of Colorectal Disease, vol. 26, no. 2, pp. 127–133, 2011.

[25] H. C. Kim, H. J. Kim, and J. C. Kim, “Reduced E-cadherin expression as a cause of distinctive signet-ring cell variant in colorectal carcinoma,” Journal of Korean Medical Science, vol. 17, no. 1, pp. 23–28, 2002.

[26] J. Y. Nam, B. Y. Oh, H. K. Hong et al., “Molecular characterization of colorectal signet-ring cell carcinoma using whole-exome and RNA sequencing,” Translational Oncology, vol. 11, no. 4, pp. 836–844, 2018.

[27] M. Seo, T. Nakahara, M. Okada et al., “Preoperative diagnosis of a small, depressed rectal cancer complicating ulcerative colitis: report of a case,” Diseases of the Colon & Rectum, vol. 38, no. 3, pp. 313–317, 1995.
[28] O. Tamai, M. Matsumoto, T. Miyaguni, M. Shiraishi, M. Yamazato, and Y. Muto, “Colon cancer in pregnancy: report of a case and review of the literature,” *Digestive Surgery*, vol. 14, no. 3, pp. 198–201, 1997.

[29] S. Shimizu, S. Myojo, M. Nagashima et al., “A patient with rectal cancer associated with ulcerative colitis in whom endoscopic ultrasonography was useful for diagnosis,” *Journal of Gastroenterology*, vol. 34, no. 4, pp. 516–519, 1999.

[30] J. T. Posey, E. Z. Neulander, M. S. Soloway, and F. Civantos, “Primary signet-ring cell carcinoma mimicking a pulled-through sigmoid colon: case report and review of the literature,” *Urology*, vol. 55, no. 6, p. 949, 2000.

[31] S. Nakata, S. Tamura, S. Morishita, and S. Onishi, “Depressed type primary signet ring cell carcinoma of the colon: a case report,” *Gastrointestinal Endoscopy*, vol. 54, no. 1, pp. 108–110, 2001.

[32] H. E. Achneck, S. K. Pradhan, S. M. Kavic, and W. E. Longo, “Primary signet-ring cell carcinoma mimicking segmental Crohn’s colitis,” *Digestive and Liver Disease*, vol. 37, no. 7, pp. 537–541, 2005.

[33] S. Kilickap, S. Aksoy, M. Dinçer, E. A. Saglam, and Ş. Yalçın, “Cutaneous metastases of signet cell carcinoma of the rectum without accompanying visceral involvement,” *Southern Medical Journal*, vol. 99, no. 10, pp. 1137–1139, 2006.

[34] B. E. Maltz and D. A. Schwartz, “Metastatic signet-ring carcinoma of the colon diagnosed by EUS-guided FNA in a patient with Crohn’s disease,” *Gastrointestinal Endoscopy*, vol. 65, no. 6, pp. 945–947, 2007.

[35] H. Derici, Y. Peker, F. Tatar, N. Cin, and V. Deniz, “Multiple malign gastrointestinal polyps and rectal carcinoma in a young patient with Peutz-Jeghers syndrome,” *International Journal of Colorectal Disease*, vol. 22, no. 1, pp. 85–86, 2007.

[36] F. Selcukbiricik, D. Tural, A. Bay, G. Sahingoz, S. Ilvan, and N. M. Mandel, “A malignant mass in the breast is not always breast cancer,” *Case Reports in Oncology*, vol. 4, no. 3, pp. 521–525, 2011.

[37] M. Canepa, P. T. Fanta, N. Weidner, and M. R. Peterson, “Schistosomiasis and signet ring cell carcinoma of the rectum,” *Annals of Diagnostic Pathology*, vol. 16, no. 5, pp. 385–387, 2012.

[38] N. C. Charles, D. D. Ng, and C. I. Zoumalan, “Signet cell adenocarcinoma of the rectum metastatic to the orbit,” *Ophthalmic Plastic & Reconstructive Surgery*, vol. 28, no. 1, pp. e1–e2, 2012.

[39] R. S. Mehta, P. Ennis, and J. Whitten, “Ureterosigmoidostomy associated signet ring colon cancer presenting as hip pain,” *Journal of Gastrointestinal Cancer*, vol. 43, no. 1, pp. 122–127, 2012.

[40] H. Shaaaban, K. Kapila, E. K. Mostafa, H. Amanguo, G. H. Hebb, and I. Francis, “Signet-ring cell adenocarcinoma of rectum with breast metastases diagnosed on FNA cytology: case report and literature review,” *Cytopathology*, vol. 24, no. 6, pp. 396–398, 2013.

[41] B. Kendre, C. Deopujari, V. Karmarkar, and V. Ratha, “A rare case of carcinoma rectum metastasizing to clivus,” *Neurology India*, vol. 62, no. 1, pp. 85–86, 2014.

[42] A. K. Dhull, P. Gogia, R. Atri et al., “Exploring signet-ring cells in pregnant female,” *Journal of Gastrointestinal Oncology*, vol. 6, no. 2, pp. E10–E15, 2015.

[43] J. Santos-Antunes, R. Goncalves, S. Lopes, and G. Macedo, “Coloduodenal fistula due to signet-ring cells adenocarci-

нома,” *International Journal of Colorectal Disease*, vol. 30, no. 10, p. 1423, 2015.

[44] J. Yadav, S. K. Yadav, K. Gaurav, A. Ahmed, K. A. Reddy, and O. Prakash, “Primary signet ring cell carcinoma of rectum: a rare entity with unusual presentation,” *International Journal of Colorectal Disease*, vol. 30, no. 5, pp. 709-710, 2015.

[45] P. Y. Park, T. Goldin, J. Chang, M. Markman, and M. N. Kundranda, “Signet-ring cell carcinoma of the colon: a case report and review of the literature,” *Case Reports in Oncology*, vol. 8, no. 3, pp. 466–471, 2015.

[46] L. Turati, F. Steccanella, F. Petrelli, E. Vitali, S. Barni, and G. Sgroi, “Signet-ring cell carcinoma of the rectum and synchronous renal cell carcinoma in a young man,” *International Journal of Colorectal Disease*, vol. 31, no. 5, pp. 1071-1072, 2016.

[47] X. C. Zhou and Y. Jiang, “Colonic carcinoma metastatic to the left testis, epididymis & spermatic cord,” *Indian Journal of Medical Research*, vol. 143, no. 6, pp. 836-837, 2016.

[48] A. Lusilla and J. de Tomás, “Leptomeningeal carcinomatosis in a young patient with obstructive colorectal signet-ring cell adenocarcinoma,” *Revista Española de Enfermedades Digestivas*, vol. 109, no. 7, p. 535, 2017.

[49] J. Ren, Z. Huo, X. Wang, Y. Liu, and G. Yang, “Serial renography for evaluation of the impact of capcitabine therapy on renal function: a case report,” *Medicine*, vol. 96, no. 22, article e8661, 2017.